Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Next Previous
Trial Profile

A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BEAM 302 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Beam Therapeutics

Most Recent Events

  • 06 May 2025 According to Beam Therapeutics media release, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Updated Data Expected to be Presented in Second Half of 2025.
  • 05 Apr 2025 According to Beam Therapeutics media release, company recently announced the clearance of its investigational drug application (IND) for BEAM-302 by the United States (U.S.) Food and Drug Administration (FDA), enabling the company to activate sites in the U.S. for its ongoing Phase 1/2 trial.
  • 05 Apr 2025 Results presented in a Beam Therapeutics media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top